Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hartmut Goldschmidt

Showing results (431-440 of 539) with videos related to

Pageof 54
Sort By:
Haematologica|December 7, 2014
The 7p15.3 (rs4487645) association for multiple myeloma shows strong allele-specific regulation of the MYC-interacting gene CDCA7L in malignant plasma cellsNiels Weinhold, Tobias Meissner, David C Johnson, et al.
Lancet (London, England)|December 15, 2018
Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trialMeletios A Dimopoulos, Francesca Gay, Fredrik Schjesvold, et al.
Leukemia|January 15, 2025
Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgroups of the MAIA studyPhilippe Moreau, Thierry Facon, Saad Z Usmani, et al.
Leukemia|September 25, 2024
LocoMMotion: a study of real-life current standards of care in triple-class exposed patients with relapsed/refractory multiple myeloma - 2-year follow-up (final analysis)María-Victoria Mateos, Katja Weisel, Valerio De Stefano, et al.
Leukemia|July 21, 2020
Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of ageElias K Mai, Kaya Miah, Uta Bertsch, et al.
Blood Cancer Journal|December 3, 2021
Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentageCarlos Fernández de Larrea, Robert Kyle, Laura Rosiñol, et al.
Haematologica|July 7, 2017
Genome-wide association study of clinical parameters in immunoglobulin light chain amyloidosis in three patient cohortsIman Meziane, Stefanie Huhn, Miguel Inacio da Silva Filho, et al.
Investigative Radiology|October 18, 2022
Deep Learning for Automatic Bone Marrow Apparent Diffusion Coefficient Measurements From Whole-Body Magnetic Resonance Imaging in Patients With Multiple Myeloma: A Retrospective Multicenter StudyMarkus Wennmann, Peter Neher, Nikolas Stanczyk, et al.
Scientific Reports|October 10, 2025
Automated radiomics model for prediction of therapy response and minimal residual disease from baseline MRI in multiple myelomaFabian Bauer, Marina Hajiyianni, Niels Weinhold, et al.
Blood Cancer Journal|March 7, 2023
Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUSPhilippe Moreau, Ajai Chari, Albert Oriol, et al.
Pageof 54

Showing results (431-440 of 539) with videos related to

Sort By:
Pageof 54
Haematologica|December 7, 2014
The 7p15.3 (rs4487645) association for multiple myeloma shows strong allele-specific regulation of the MYC-interacting gene CDCA7L in malignant plasma cellsNiels Weinhold, Tobias Meissner, David C Johnson, et al.
Lancet (London, England)|December 15, 2018
Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trialMeletios A Dimopoulos, Francesca Gay, Fredrik Schjesvold, et al.
Leukemia|January 15, 2025
Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgroups of the MAIA studyPhilippe Moreau, Thierry Facon, Saad Z Usmani, et al.
Leukemia|September 25, 2024
LocoMMotion: a study of real-life current standards of care in triple-class exposed patients with relapsed/refractory multiple myeloma - 2-year follow-up (final analysis)María-Victoria Mateos, Katja Weisel, Valerio De Stefano, et al.
Leukemia|July 21, 2020
Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of ageElias K Mai, Kaya Miah, Uta Bertsch, et al.
Blood Cancer Journal|December 3, 2021
Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentageCarlos Fernández de Larrea, Robert Kyle, Laura Rosiñol, et al.
Haematologica|July 7, 2017
Genome-wide association study of clinical parameters in immunoglobulin light chain amyloidosis in three patient cohortsIman Meziane, Stefanie Huhn, Miguel Inacio da Silva Filho, et al.
Investigative Radiology|October 18, 2022
Deep Learning for Automatic Bone Marrow Apparent Diffusion Coefficient Measurements From Whole-Body Magnetic Resonance Imaging in Patients With Multiple Myeloma: A Retrospective Multicenter StudyMarkus Wennmann, Peter Neher, Nikolas Stanczyk, et al.
Scientific Reports|October 10, 2025
Automated radiomics model for prediction of therapy response and minimal residual disease from baseline MRI in multiple myelomaFabian Bauer, Marina Hajiyianni, Niels Weinhold, et al.
Blood Cancer Journal|March 7, 2023
Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUSPhilippe Moreau, Ajai Chari, Albert Oriol, et al.
Pageof 54